NASDAQ:ARWRArrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARWR stock has increased by 55.8% and is now trading at $44.51. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.09. The biotechnology company had revenue of $23.53 million for the quarter, compared to analysts' expectations of $21.90 million. Arrowhead Pharmaceuticals had a return on equity of 2.61% and a net margin of 6.86%. View Arrowhead Pharmaceuticals' earnings history.

10 equities research analysts have issued 1-year price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $29.00 to $81.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $62.00 in the next year. This suggests a possible upside of 39.3% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals.

Media stories about ARWR stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Arrowhead Pharmaceuticals.

Some companies that are related to Arrowhead Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN) and Mylan (MYL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Alliance Resource Partners (ARLP), Sasol (SSL), Sarepta Therapeutics (SRPT) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%) and Defender Capital LLC. (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View institutional ownership trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Michael S Perry, and Patrick O'brien. View insider buying and selling activity for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC.. View insider buying and selling activity for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $44.51.

Arrowhead Pharmaceuticals has a market capitalization of $4.53 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]